Pramod K Srivastava PhD MD
机构: University of Connecticut School of Medicine
每年引用次数
引用次数
引用: 34,365
H-指数: 87
I10-指数 : 215
出版物: 346
Isolation of MHC Class I-Restricted Tumor Antigen Peptide and Its Precursors Associated with Heat Shock Proteins hsp70, hsp90, and gp96
Akio Hizuta , Heiichiro Udono , Pramod K. Srivastava , Toshiro Ono
Journal of Immunology 162 ( 3) 1303 -1309
228
1999
A novel heteromorphic human cell surface alloantigen, gp60, defined by a human monoclonal antibody.
Pramod K. Srivastava , Hiroshi Yamaguchi , Lloyd J. Old , Dirk Schadendorf
Journal of Immunology 142 ( 5) 1621 -1625
11
1989
Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70.
Heiichiro Udono , Pramod K. Srivastava
Journal of Immunology 152 ( 11) 5398 -5403
422
1994
Naturally formed or artificially reconstituted non-covalent alpha2-macroglobulin-peptide complexes elicit CD91-dependent cellular immunity
Pramod K. Srivastava , Robert J. Binder , Sumeet K. Kumar
Cancer Immunity Archive 2 ( 1) 16
23
2002
Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
Pramod K. Srivastava , Rajiv Y. Chandawarkar
57
1998
Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
Pramod K. Srivastava , Zihai Li
36
2003
Identification of chaperones as essential components of the tumor rejection moieties of cancers
Pramod K. Srivastava
Cancer Immunity Archive 12 ( 1) 5 -5
2
2012
High efficiency CD91- and LOX-1-mediated re-presentation of gp96-chaperoned peptides by MHC II molecules.
Tatsuya Sawamura , Pramod K. Srivastava , Toyoshi Matsutake
Cancer Immunity Archive 10 ( 1) 7 -7
45
2010
Hypothesis: Controlled necrosis as a tool for immunotherapy of human cancer
Pramod K. Srivastava
Cancer Immunity Archive 3 ( 1) 4
40
2003
Use of heat shock protein 70 preparations in vaccination against cancer and infectious disease
Pramod K. Srivastava
49
2002
Expression of a Shared Tumor-specific Antigen by Two Chemically Induced BALB/c Sarcomas
Albert B. DeLeo , Herbert F. Oettgen , Pramod K. Srivastava , Michael A. Palladino
Cancer Research 47 ( 19) 5074 -5079
111
1987
An open invitation to the cancer immunology community
Pramod K. Srivastava , James P. Allison , Vincenzo Cerundolo , Alexander Knuth
Cancer Immunity Archive 12 ( 1) 1 -1
10
2012
Mechanism of dichotomy between CD8+ responses elicited by apoptotic and necrotic cells
Matthew R. Buckwalter , Pramod K. Srivastava
Cancer Immunity Archive 13 ( 1) 2 -2
12
2013
Identification of a human homologue of the murine tumor rejection antigen GP96.
Pramod K. Srivastava , Lloyd J. Old
Cancer Research 49 ( 6) 1341 -1343
40
1989
Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer.
Vincenzo Mazzaferro , Tiziana Camerini , Giorgio Parmiani , Licia Rivoltini
Clinical Cancer Research 9 ( 9) 3235 -3245
224
2003
Molecular nature of the antigenic entity transferred from antigen donor cell to antigen presenting cells during cross presentation
Manish Garg , Pramod K. Srivastava
Cancer Immunity Archive 8 11
2008
Adoptive immunotherapy utilizing heat shock/stress protein-peptide complexes for prevention/treatment of cancer or infectious diseases
Pramod K. Srivastava
4
1998
Identification of a tumor-associated contact-dependent activity which reversibly downregulates cytolytic function of CD8+ T cells.
Michael Heike , Heiichiro Udono , Pramod K. Srivastava , Daniel L. Levey
Cancer Immunity Archive 1 ( 1) 5 -5
7
2001
Complexes of peptide-binding fragments of heat shock proteins and their use as immunotherapeutic agents
Pramod K. Srivastava
28
2001
A heat shock protein based polyvalent vaccine targeting HSV-2: CD4(+) and CD8(+) cellular immunity and protective efficacy.
Kenneth LeClair , Aston Liu , Roman M. Chicz , Alemseged Truneh
Vaccine 29 ( 47) 8530 -8541
35
2011